 They weren't the right plaintiffs. They didn't have enough of an injury to say that what the FDA did in making it easier to obtain Mifepristone, that that actually injured that group enough to be able to bring the case. So that was a ruling on jurisdictional issues. It didn't get to the merits of what the FDA did with respect to making it easier to obtain Mifepristone.